The Trellis management team brings more than 100 years of expertise to the discovery and development of therapeutic antibodies, leveraging the company's proprietary platform for antibody discovery.
Our Management Team
 - CEO Brian Cunningham has been a senior executive in, and advisor to, leading Bay Area biotech companies for 25 years.
- Brian Cunningham,
President and Chief Executive Officer
Before joining Trellis, Mr. Cunningham was President and Chief Operating Officer of Rigel. He was a partner at Cooley Godward Kronish, LLP, where he headed the Life Sciences Group, the Health Care Group and Patent Group. Earlier, he served as Vice President, Secretary and General Counsel of Genentech, as Associate Corporate Counsel of Monsanto, and as a securities attorney at Winthrop, Stimson, Putnam & Roberts in New York City. He is currently a director of several biotechnology companies.
|
| |
 - Chief Operating Officer Stote Ellsworth has led the engineering effort to develop Trellis technology as a robust, reliable platform.
- Stote Ellsworth,
Vice President and Chief Operating Officer
Mr. Ellsworth has been Director of Engineering at Becton Dickinson, where he was responsible for developing and commercializing numerous fluorescence activated cell sorting technology (FACS) products. Prior to that, he was Vice President of R&D and Chief Operating Officer at First Medical, a point-of-care diagnostic company. He holds a BA from Dartmouth and an MS in Electrical Engineering from Stanford University.
|
| |
 - Founder Larry Kauvar has built a 20-year reputation as an inventor of innovative platform technologies.
- Lawrence Kauvar, PhD,
Founder, Senior Vice President and Chief Scientific Officer
Dr. Kauvar is an entrepreneur
and scientist who founded
Trellis and was previously
the founder and Chief
Scientific Officer of
Telik, a small molecule
drug company focused
on oncology. He holds
40 US patents for methods,
tools and drug compounds
and is one of the inventors
of CellSpot™,
Trellis' core technology.
Dr. Kauvar holds a PhD
from Yale in Molecular
Biophysics and Biochemistry,
did his postdoctoral
studies at Caltech and
holds an undergraduate
degree from Harvard University.
|
| |
 - Chief Technical Officer Bruce Keyt has developed six marketed biologics during his 25-year career in the field of protein and antibody therapeutics.
- Bruce Keyt, PhD,
Vice President Research and Chief Technology Officer
Dr. Keyt has served as
Vice President Preclinical
Development at Abgenix,
Director Biotherapeutic
Oncology at Millennium Pharmaceuticals;
and in scientific management positions
in pharmacology, biochemistry and pharmacokinetics
at Genentech. Dr. Keyt has 18 US patents
and applications and authored over 50 scientific
publications. His PhD in Biochemistry/Pharmacology
is from Tufts University School of Medicine.
|
| |
 - EVP, Business Operations and Chief Business Officer John Wulf is a senior corporate development executive with over 20 years industry experience.
- John Wulf,
Executive Vice President, Business Operations and Chief Business Officer
Mr. Wulf joined Trellis from Y's Therapeutics, a Tokyo-based biopharmaceutical company, where he was President of U.S. Operations and COO & CBO of the parent company. He has been Senior VP of Corporate Development at InterMune, VP Business Development at Axys Pharmaceuticals and was at Genentech from 1981 to 1998. Mr. Wulf holds an MBA from San Francisco State University, an MS in Microbiology from Oregon State University and BA from UC Davis.
|
|
